Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

BACKGROUND The emergence of drug-resistant strains of bacteria has complicated treatment decisions and may lead to treatment failures. METHODS We examined data on invasive pneumococcal disease in patients identified from 1995 to 1998 in the Active Bacterial Core Surveillance program of the Centers for Disease Control and Prevention. Pneumococci that had a high level of resistance or had intermediate resistance according to the definitions of the National Committee for Clinical Laboratory Standards were defined as "resistant" for this analysis. RESULTS During 1998, 4013 cases of invasive Streptococcus pneumoniae disease were reported (23 cases per 100,000 population); isolates were available for 3475 (87 percent). Overall, 24 percent of isolates from 1998 were resistant to penicillin. The proportion of isolates that were resistant to penicillin was highest in Georgia (33 percent) and Tennessee (35 percent), in children under five years of age (32 percent, vs. 21 percent for persons five or more years of age), and in whites (26 percent, vs. 22 percent for blacks). Penicillin-resistant isolates were more likely than susceptible isolates to have a high level of resistance to other antimicrobial agents. Serotypes included in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 percent and 88 percent of penicillin-resistant strains, respectively. Between 1995 and 1998 (during which period 12,045 isolates were collected), the proportion of isolates that were resistant to three or more classes of drugs increased from 9 percent to 14 percent; there also were increases in the proportions of isolates that were resistant to penicillin (from 21 percent to 25 percent), cefotaxime (from 10 percent to 15 percent), meropenem (from 10 percent to 16 percent), erythromycin (from 11 percent to 16 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 percent). The increases in the frequency of resistance to other antimicrobial agents occurred exclusively among penicillin-resistant isolates. CONCLUSIONS Multidrug-resistant pneumococci are common and are increasing. Because a limited number of serotypes account for most infections with drug-resistant strains, the new conjugate vaccines offer protection against most drug-resistant strains of S. pneumoniae.

[1]  M. Kolczak,et al.  Incidence of Community-Acquired Pneumonia Requiring Hospitalization Results of a Population-Based Active Surveillance Study in Ohio , 1997 .

[2]  Andrew G. Dean,et al.  Epi info, version 6 : a word-processing, database, and statistics program for public health on IBM-compatible microcomputers , 1996 .

[3]  L. Brammer,et al.  Influenza surveillance--United States, 1992-93 and 1993-94. , 1997, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[4]  F. Baquero-Artigao,et al.  Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. , 1998, The Pediatric infectious disease journal.

[5]  S. Dowell,et al.  Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. , 1999, The Pediatric infectious disease journal.

[6]  G. Doern,et al.  Antimicrobial Resistance with Streptococcus Pneumoniae in the United States , 2000, Seminars in respiratory and critical care medicine.

[7]  J. Hughes,et al.  Trends in antimicrobial drug prescribing among office-based physicians in the United States. , 1995, JAMA.

[8]  M. Jacobs.  Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. , 1996, The Pediatric infectious disease journal.

[9]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[10]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[11]  R. Austrian,et al.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. , 1964, Annals of internal medicine.

[12]  A. Schuchat,et al.  Bacterial Meningitis in the United States in 1995 , 1997 .

[13]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[14]  A. Rossi,et al.  Risk Factors and Course of Illness Among Children With Invasive Penicillin-resistant Streptococcus pneumoniae , 1999 .

[15]  P. Murray,et al.  Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae , 1996, Journal of clinical microbiology.

[16]  J. B. D. Bernaldo de Quirós,et al.  Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  E. Choi,et al.  Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Ferraro,et al.  Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parELoci , 1999, Antimicrobial Agents and Chemotherapy.

[19]  J. Bartlett,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Community-Acquired Pneumonia in Adults: Guidelines for Management , 1998 .

[20]  F. Tenover,et al.  Emergence of drug-resistant pneumococcal infections in the United States. , 1994, JAMA.

[21]  A. Schuchat,et al.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.

[22]  D. Greenberg,et al.  Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? , 1997, The Journal of infectious diseases.

[23]  J. Ambler,et al.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae , 1996, Antimicrobial agents and chemotherapy.

[24]  B. Rudensky,et al.  Pneumococcal bacteremia--no change in mortality in 30 years: analysis of 104 cases and review of the literature. , 1987, Israel journal of medical sciences.

[25]  M. Pfaller,et al.  Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. , 1998, Diagnostic microbiology and infectious disease.

[26]  M. Poole,et al.  Otitis media complications and treatment failures: implications of pneumococcal resistance , 1995, The Pediatric infectious disease journal.

[27]  M. Cetron,et al.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. , 1995, The New England journal of medicine.

[28]  D. Greenberg,et al.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[29]  R. Dagan,et al.  Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. , 1997, The Pediatric infectious disease journal.

[30]  R. Bostick,et al.  Antibiotic Use in Urban Whites and Blacks: The Minnesota Heart Survey , 1992, The Annals of pharmacotherapy.

[31]  J. Justman,et al.  Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Cetron,et al.  Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. , 1998, American journal of epidemiology.

[33]  D. Sahm,et al.  In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance. , 1998, Clinical therapeutics.

[34]  A. Schuchat,et al.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. , 2000, Archives of internal medicine.

[35]  F. Tenover,et al.  Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. , 1992, The Pediatric infectious disease journal.

[36]  S. Dowell,et al.  Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  G. Doern,et al.  Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. , 1999, Emerging infectious diseases.

[38]  J. Klein,et al.  The problem of resistant bacteria for the management of acute otitis media. , 1995, Pediatric clinics of North America.

[39]  S. Buckingham,et al.  Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. , 1998, The Journal of pediatrics.